公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

不劳无获:如何获取钢镚? 因为论坛,所以相逢。 捐赠百科答题至尊

公卫考研:一起风雨兼程 因为梦想,所以努力。 真题答案政治英语

职称考试:诸君逢考必过 因为热爱,所以执着。 模拟考场技能执医中级

今日头条(欢迎原创,积极回帖讨论。帖子内请勿发广告和QQ群及其他私货,否则会被禁言)

查看: 2451|回复: 5

[分享] Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA

[复制链接]
sampson2010 发表于 2015-1-29 11:29:04 | 显示全部楼层 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 sampson2010 于 2015-1-29 11:33 编辑 & d! H6 M0 |* `+ m- O. W

$ H6 r2 |' ?- J2 F. Q2 t8 C7 v* c  ] 01f6de49a7e4a23bfeaeffa1fbe8a784-d.jpg 4 q( Y7 Q" g' E5 p- V& D; W
5 n* m5 Z2 W- u, \3 @6 ~$ X
Title: Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
. L4 b6 w9 C& N7 }8 }8 A/ _6 NAuthor(s): Tom Brody PhD University of California at Berkeley
: o# N3 b: k0 c/ oPublisher: Academic Press        1 r& }/ B3 N0 T% _. {' J. t+ Z
Year: 2011
0 \3 t4 v% t2 r. y- Y5 YEdition: 19 v/ y. J* `2 f& w) a* n* B6 w
Language: English        8 I: C; k9 T0 q& a5 n
Pages: 638
0 x0 K1 I" l. J0 ]: vSize: 7 MB (7293100 bytes)       
3 h4 u/ G$ {/ ~( L2 }' CExtension: pdf
9 c$ [. \- L! H8 x( M. R. C+ }
8 Q& U1 ~3 L# I' ]" N
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understanding of how to conduct clinical trials. It will also act as a guide for the more experienced by detailing endpoint selection and illustrating how to avoid unnecessary pitfalls. This book is a straightforward and valuable reference for all those involved in clinical trial design. # F1 \# q0 K3 P0 l3 N9 `1 v
Provides extensive coverage of the "study schema" and related features of study designOffers a "hands-on" reference that contains an overview of the process, but more importantly details a step-by-step account of clinical trial designFeatures examples from the medical literature to highlight how investigators choose the most suitable endpoint(s) for clinical trial and includes graphs from real clinical trials to help explain each concept in study designIntegrates clinical trial design, pharmacology, biochemistry, cell biology and legal aspects to provide readers with a comprehensive look at all aspects of clinical trialsIncludes chapters on core material and important ancillary topics, such as package inserts, consent forms, and safety reporting forms used in the United States, England and Europe
2 k: D- z) y  T) RFor complimentary access to our sample chapter (chapter 24), please copy and paste this link into your browser: http://tinyurl.com/awwutvn
& h! X- s7 o8 o3 ]
/ i( I0 I% I5 d6 Y0 @0 ETable of contents :
, H) Y$ b. R) r2 |% H) k. [Content:
+ y* W0 x2 [! p4 P5 ^3 I! F8 v  MFront-matter, Pages i,iii0 l% ]/ s9 t. R
Copyright, Page iv
0 j' r1 j! C  T0 X3 ?Dedication, Page v. v0 z- ?! L5 n1 J4 C! O, J2 {6 q0 y5 f
Acknowledgments, Pages xv-xvi
7 ^$ X5 G. O: ?0 rPreface, Pages xvii-xxi0 y% m% D* F7 Y: ~, W1 H
Introduction, Pages xxiii-xxv, z& g* n5 @2 _& f9 E
Abbreviations and Definitions, Pages xxvii-xxxi
- Y) W. V- a! J  g" ~Biography, Page xxxiii
2 _7 c7 y# y, ?6 P0 ~, w, qChapter 1 - The Origins of Drugs, Pages 1-15/ x" H# Z3 F$ K- d& U
Chapter 2 - Introduction to Regulated Clinical Trials, Pages 17-507 X: N+ L) s, S' a' K& k: I( b
Chapter 3 - Run-in Period, Pages 51-61
. e6 P6 i0 W  a8 [Chapter 4 - Inclusion/Exclusion Criteria, Stratification, and Subgroups – Part I, Pages 63-89
4 ]  r4 e6 m/ z; fChapter 5 - Inclusion and Stratification Criteria – Part II, Pages 91-110
8 T- O" G$ W3 o$ D0 g  T+ Y2 R* oChapter 6 - Randomization, Allocation, and Blinding, Pages 111-129
% I) J% n1 G; V1 `' c3 i, @Chapter 7 - Placebo Arm as Part of Clinical Study Design, Pages 131-141- s# C- `: c, \3 |7 M2 s
Chapter 8 - Intent to Treat Analysis vs. Per Protocol Analysis, Pages 143-164* T2 y2 V/ Q" {- V
Chapter 9 - Biostatistics, Pages 165-190
0 ]) Z1 ?' t( B% {7 |Chapter 10 - Introduction to Endpoints for Clinical Trials in Pharmacology, Pages 191-195
3 F/ N. T8 ~) r. ZChapter 11 - Endpoints in Clinical Trials on Solid Tumors – Objective Response, Pages 197-211# u8 V5 k1 b+ N# E% A. j
Chapter 12 - Oncology Endpoints: Overall Survival and Progression-free Survival, Pages 213-236
( s( u! J, V& y  q  \  HChapter 13 - Oncology Endpoints: Time to Progression, Pages 237-250" p. ^5 N2 {3 v7 O4 Z
Chapter 14 - Oncology Endpoint: Disease-Free Survival, Pages 251-261
( ^" [2 t7 z' ?4 C2 Z2 C1 h9 Y+ c/ qChapter 15 - Oncology Endpoint: Time to Distant Metastasis, Pages 263-2707 c  S8 p- F) w3 h. O1 ]# x1 B+ {
Chapter 16 - Neoadjuvant Therapy versus Adjuvant Therapy, Pages 271-277( i; P" s' ~; y9 r" o  a
Chapter 17 - Hematological Cancers, Pages 279-325* U: I. Z) n* h! b; c
Chapter 18 - Biomarkers and Personalized Medicine, Pages 327-353
7 g( t8 f; p: o4 \: u9 t1 R7 EChapter 19 - Endpoints in Immune Diseases, Pages 355-367; m9 @/ F' O% e3 V4 Z" M0 m2 r2 D% R
Chapter 20 - Endpoints in Clinical Trials on Infections, Pages 369-382
; U. ]' k0 x5 Y9 uChapter 21 - Health-Related Quality of Life, Pages 383-4003 y# h5 O6 O  |) {
Chapter 22 - Health-Related Quality of Life Instruments for Immune Disorders, Pages 401-410
" S. k6 ]; N. e7 rChapter 23 - Health-Related Quality of Life Instruments and Infections, Pages 411-414
6 K/ s( j. E  HChapter 24 - Drug Safety, Pages 415-469+ K7 Y  {# h3 t. u* P
Chapter 25 - Mechanism of Action, Part I, Pages 471-491
' b* I0 O# s5 ^5 L5 E7 ~Chapter 26 - Mechanisms of Action, Part II – Cancer, Pages 493-501
; R! y! F* I5 B' v) C2 o7 |" F4 X0 wChapter 27 - Mechanisms of Action, Part III – Immune Disorders, Pages 503-515
& S2 M4 c' Z, y0 UChapter 28 - Mechanisms of Action, Part IV – Infections, Pages 517-5336 [# n0 X7 q- A& x
Chapter 29 - Consent Forms, Pages 535-559
0 Y' x0 i6 I$ ?1 Y! `Chapter 30 - Package Inserts, Pages 561-5759 D5 ~$ K7 v3 U" `4 c+ T) d
Chapter 31 - Regulatory Approval, Pages 577-605
, u. Y. P- m: e  M, rChapter 32 - Patents, Pages 607-623
# _% Y" p  M  e+ F4 G) XIndex, Pages 625-638
4 b+ D! k8 l+ {  c- Z' B& \% C5 p0 d& d0 u1 a
Clinical Trials Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and.pdf (6.96 MB, 下载次数: 128)

评分

参与人数 1金钱 +20 收起 理由
hoozoo + 20 积极发布原创帖子内容,再接再厉!

查看全部评分

本帖被以下淘专辑推荐:

biostat 发表于 2015-3-3 09:20:10 | 显示全部楼层
赞一个!
回复

使用道具 举报

AprilChen0424 发表于 2016-11-6 17:36:05 | 显示全部楼层
谢谢,这本guideline吧信息整合得很全,值得一读
回复

使用道具 举报

ghgzw 发表于 2016-11-12 19:39:36 | 显示全部楼层
谢谢,可惜是第一版的。
回复

使用道具 举报

ling820927 发表于 2017-3-1 14:29:31 | 显示全部楼层
怎么下载不来
回复

使用道具 举报

liuql10 发表于 2017-6-4 16:29:39 | 显示全部楼层
哇,太棒的书!谢谢楼主分享
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

安卓版|我要捐赠|关于我们|接种问答|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2017-10-18 04:26 , Processed in 0.180706 second(s), 46 queries , Gzip On, MemCache On.

Powered by Discuz! X3.3

© 2001-2017 Comsenz Inc.

快速回复 返回顶部 返回列表